Lennar Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Lennar Corporation trades at $82.92 (market cap $19.92B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Lennar Corporation and Zimmer Biomet Holdings Inc are close in size by market cap, and Lennar Corporation pays the higher dividend (2.41%). Which is the better fit depends on your goals.
| LEN | ZBH | |
|---|---|---|
Market Cap | $19.92B | $17.36B |
Sector | Consumer Cyclical | Health |
52-Week High | $142.40 | $107.71 |
52-Week Low | $82.30 | $79.58 |
Enterprise Value | $23.80B | $24.40B |
Dividend Yield | 2.41% | 1.07% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Trailing returns across standard periods
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →